Literature DB >> 16131416

Update on dementia with Lewy bodies.

David J Burn1.   

Abstract

Dementia with Lewy bodies (DLB) presents to a range of specialists and involves a number of management challenges. The nosologic status of the disorder is controversial, especially its clinical overlap with Parkinson's disease-related dementia and its pathologic distinction from Alzheimer's disease. This article considers some of the controversies surrounding DLB with reference to recent literature. Emphasis is given to clinical topics, including the clinical phenomenology, differential diagnosis, and the treatment of core features of the disease.

Entities:  

Mesh:

Year:  2005        PMID: 16131416     DOI: 10.1007/s11910-005-0057-5

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  39 in total

1.  Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease.

Authors:  T A Ala; L F Hughes; G A Kyrouac; M W Ghobrial; R J Elble
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-04       Impact factor: 10.154

2.  Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.

Authors:  Clive Ballard; Marisa Margallo-Lana; Edmund Juszczak; Simon Douglas; Alan Swann; Alan Thomas; John O'Brien; Anna Everratt; Stuart Sadler; Clare Maddison; Lesley Lee; Carol Bannister; Ruth Elvish; Robin Jacoby
Journal:  BMJ       Date:  2005-02-18

3.  Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial.

Authors:  J Grace; S Daniel; T Stevens; K K Shankar; Z Walker; E J Byrne; S Butler; D Wilkinson; J Woolford; J Waite; I G McKeith
Journal:  Int Psychogeriatr       Date:  2001-06       Impact factor: 3.878

4.  The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia.

Authors:  M P Walker; G A Ayre; J L Cummings; K Wesnes; I G McKeith; J T O'Brien; C G Ballard
Journal:  Br J Psychiatry       Date:  2000-09       Impact factor: 9.319

5.  A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping.

Authors:  Sean J Colloby; John D Fenwick; E David Williams; Sean M Paling; Kyriakos Lobotesis; Clive Ballard; Ian McKeith; John T O'Brien
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-05       Impact factor: 9.236

6.  Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies.

Authors:  Ian G McKeith; Keith A Wesnes; Elaine Perry; Roberto Ferrara
Journal:  Dement Geriatr Cogn Disord       Date:  2004-04-14       Impact factor: 2.959

7.  L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia.

Authors:  S B Bonelli; G Ransmayr; M Steffelbauer; T Lukas; C Lampl; M Deibl
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

8.  Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study.

Authors:  David J Burn; Elise N Rowan; Thais Minett; Jonathon Sanders; Pat Myint; Jonathon Richardson; Alan Thomas; Jane Newby; Jenny Reid; John T O'Brien; Ian G McKeith
Journal:  Mov Disord       Date:  2003-08       Impact factor: 10.338

9.  Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.

Authors:  Enrique Noe; Karen Marder; Karen L Bell; Diane M Jacobs; Jennifer J Manly; Yaakov Stern
Journal:  Mov Disord       Date:  2004-01       Impact factor: 10.338

10.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.

Authors:  John E Duda; Benoit I Giasson; Meghann E Mabon; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

View more
  1 in total

1.  Different Clinical and Neuroimaging Characteristics in Early Stage Parkinson's Disease with Dementia and Dementia with Lewy Bodies.

Authors:  Mami Takemoto; Kota Sato; Noriko Hatanaka; Toru Yamashita; Yasuyuki Ohta; Nozomi Hishikawa; Koji Abe
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.